Dominique Griffin, NP
Psychiatric/Mental Health · Culver City, CANPI 1164946992
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 30.3% of the total. Reporting peaked in 2024 at $1,740 and has fallen 55.9% since, to $768 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$974
- Alkermes, Inc.$797
- Indivior Inc.$361
- Vanda Pharmaceuticals Inc.$248
- Otsuka America Pharmaceutical, Inc.$177
- plus $502 from 5 others
What the payments were for
- Food & beverage$4,391100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 107 | $1,331 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $974 |
| Alkermes, Inc. | 45 | $797 |
| Indivior Inc. | 12 | $361 |
| Vanda Pharmaceuticals Inc. | 12 | $248 |
| Otsuka America Pharmaceutical, Inc. | 9 | $177 |
| Sunovion Pharmaceuticals Inc. | 8 | $153 |
| Neurocrine Biosciences, Inc. | 7 | $105 |
| AbbVie | 5 | $103 |
| Lundbeck LLC | 4 | $94 |
| Boston Scientific | 2 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$434
- CAPLYTA$299
- INVEGA SUSTENNA$142
- INVEGA TRINZA$142
- PERSERIS$123
- ARISTADA INITIO$109
How this compares
$4,391 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 104 | $304,401 |
| Abilify MaintenaAripiprazole | 43 | $125,069 |
| IngrezzaValbenazine Tosylate | 11 | $84,408 |
| Aripiprazole | 277 | $30,306 |
| Lurasidone Hcl | 48 | $26,787 |
| CaplytaLumateperone Tosylate | 15 | $26,156 |
| Risperidone OdtRisperidone | 124 | $25,412 |
| Olanzapine OdtOlanzapine | 157 | $22,547 |
| Quetiapine Fumarate | 740 | $14,157 |
| Chlorpromazine Hcl | 55 | $13,849 |
| Divalproex Sodium ErDivalproex Sodium | 261 | $13,106 |
| Fluphenazine Hcl | 48 | $12,425 |
| Risperidone | 479 | $11,805 |
| Olanzapine | 486 | $10,336 |
| Paliperidone ErPaliperidone | 24 | $8,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,331 | $304,401104 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $177 | $125,06943 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $105 | $84,40811 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $974 | $26,15615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Culver City
- Joseph WeigelCulver City$18K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.